Glanbia PLC (GL9)
Irish Exchange · Ireland · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 20.60 |
|---|---|
| 52-week range | 14.09 – 25.10 |
| Return, 1 month / 3 months | +3.2% / −9.1% |
| Return, 1 year / 3 years | +38.4% / +41.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 56 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -24.9% |
| Average daily value traded | 10.22M EUR |
| Dividend yield | 2.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Glanbia PLC is an Irish nutrition and ingredients company. It makes dairy and nutritional ingredients, including whey protein and cheese, and supplies sports nutrition and health products to food manufacturers, retailers and consumers. Its branded sports nutrition lines are sold in many markets, while its ingredient operations serve food and beverage producers. The company is based in Ireland and operates internationally across the nutrition and dairy sectors.
Glanbia PLC trades under the code GL9 on the Irish Exchange in Ireland, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Glanbia PLC (GL9) trades on the Irish Exchange in Ireland. It last closed at EUR 20.60 on 22 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 13 of 21 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 38.4% and over the last three months it fell 9.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Irish Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 3.9% | ||
| From 52-week high | -17.1% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.1% | ||
| 6-month return | 19.4% | ||
| 12-month return, skipping the last month | 34.1% | ||
| Stability (higher is calmer) | 45 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.9% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 10.22M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 71 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 2.2% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.3% |
|---|---|
| 1 month | +3.2% |
| 3 months | −9.1% |
| 6 months | +19.4% |
| 1 year | +38.4% |
| 3 years | +41.5% |
| 5 years | +55.3% |
Signals
| 50-day / 200-day average | 20.90 / 19.83 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Aug 2026 | EUR 0.1892 |
| 19 Mar 2026 | EUR 0.2567 |
| 21 Aug 2025 | EUR 0.1720 |
| 20 Mar 2025 | EUR 0.2333 |
| 22 Aug 2024 | EUR 0.1564 |
| 21 Mar 2024 | EUR 0.2121 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Irish Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.